ERAS
Price
$11.24
Change
+$0.65 (+6.14%)
Updated
Feb 4 closing price
Capitalization
3.48B
42 days until earnings call
Intraday BUY SELL Signals
GLUE
Price
$19.53
Change
-$1.40 (-6.69%)
Updated
Feb 4 closing price
Capitalization
1.49B
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs GLUE

Header iconERAS vs GLUE Comparison
Open Charts ERAS vs GLUEBanner chart's image
Erasca
Price$11.24
Change+$0.65 (+6.14%)
Volume$4.11M
Capitalization3.48B
Monte Rosa Therapeutics
Price$19.53
Change-$1.40 (-6.69%)
Volume$1.12M
Capitalization1.49B
ERAS vs GLUE Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
GLUE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. GLUE commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and GLUE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ERAS: $11.24 vs. GLUE: $19.53)
Brand notoriety: ERAS and GLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 69% vs. GLUE: 62%
Market capitalization -- ERAS: $3.48B vs. GLUE: $1.49B
ERAS [@Biotechnology] is valued at $3.48B. GLUE’s [@Biotechnology] market capitalization is $1.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileGLUE’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • GLUE’s FA Score: 1 green, 4 red.
According to our system of comparison, GLUE is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while GLUE’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 5 bearish.
  • GLUE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +10.96% price change this week, while GLUE (@Biotechnology) price change was -7.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.41%. For the same industry, the average monthly price growth was +1.41%, and the average quarterly price growth was +32.47%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

GLUE is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (-2.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($3.48B) has a higher market cap than GLUE($1.49B). ERAS YTD gains are higher at: 202.151 vs. GLUE (24.554). GLUE has higher annual earnings (EBITDA): 16.8M vs. ERAS (-131.32M). GLUE has more cash in the bank: 391M vs. ERAS (288M). GLUE has less debt than ERAS: GLUE (40.2M) vs ERAS (48.3M). GLUE has higher revenues than ERAS: GLUE (182M) vs ERAS (0).
ERASGLUEERAS / GLUE
Capitalization3.48B1.49B233%
EBITDA-131.32M16.8M-782%
Gain YTD202.15124.554823%
P/E RatioN/A61.09-
Revenue0182M-
Total Cash288M391M74%
Total Debt48.3M40.2M120%
TECHNICAL ANALYSIS
Technical Analysis
ERASGLUE
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 3 days ago
89%
Declines
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 7 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
GLUE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARRZX13.300.33
+2.54%
AMG River Road Focused Absolute Value Z
CDOZX43.870.41
+0.94%
Columbia Dividend Opportunity Inst
NSCAX50.960.05
+0.10%
Nuveen Small-Cap Value Opps A
DDIAX16.03N/A
N/A
Nomura Wealth Builder A
MIGCX53.73-0.41
-0.76%
Invesco Main Street C

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been closely correlated with STRO. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLUE jumps, then STRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-6.69%
STRO - GLUE
68%
Closely correlated
+0.40%
ACET - GLUE
68%
Closely correlated
-3.51%
GLSI - GLUE
67%
Closely correlated
-3.62%
ERAS - GLUE
67%
Closely correlated
+6.19%
TERN - GLUE
66%
Closely correlated
-6.39%
More